Patents Assigned to DS PHARMA ANIMAL HEALTH CO., LTD.
  • Publication number: 20200323826
    Abstract: The present invention relates to a sustained-release pharmaceutical composition intended for animal use, which comprises a drug, a sugar, a wax, and a water-soluble polymer.
    Type: Application
    Filed: May 6, 2020
    Publication date: October 15, 2020
    Applicant: DS PHARMA ANIMAL HEALTH CO., LTD.
    Inventor: Teruaki KURIYAMA
  • Patent number: 10695420
    Abstract: The present invention provides a combination preparation for inducing a specific immune response to an antigenic peptide, which contains (I) the antigenic peptide, and (II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide, into which the antigenic peptide has been inserted or added, wherein said antigenic peptide is inserted in a region of amino acid residues 74-87 or 130-138 of the hepatitis B virus core antigen polypeptide, or added to the N-terminal or C-terminal of the hepatitis B virus core antigen polypeptide, wherein the antigenic peptide of (I) and the expression vector of (II) are substantially simultaneously administered to a subject.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: June 30, 2020
    Assignees: ANGES, INC., OSAKA UNIVERSITY, DS PHARMA ANIMAL HEALTH CO., LTD.
    Inventors: Hironori Nakagami, Ryuichi Morishita, Hiroshi Koriyama, Hideki Tomioka, Kenji Naohara
  • Publication number: 20190142808
    Abstract: The present invention relates to a sustained-release pharmaceutical composition intended for animal use, which comprises a drug, a sugar, a wax, and a water-soluble polymer.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 16, 2019
    Applicant: DS Pharma Animal Health Co., Ltd.
    Inventor: Teruaki KURIYAMA
  • Publication number: 20170258895
    Abstract: The present invention provides a combination preparation for inducing a specific immune response to an antigenic peptide, which contains (I) the antigenic peptide, and (II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide, into which the antigenic peptide has been inserted or added, wherein said antigenic peptide is inserted in a region of amino acid residues 74-87 or 130-138 of the hepatitis B virus core antigen polypeptide, or added to the N-terminal or C-terminal of the hepatitis B virus core antigen polypeptide, wherein the antigenic peptide of (I) and the expression vector of (II) are substantially simultaneously administered to a subject.
    Type: Application
    Filed: November 20, 2015
    Publication date: September 14, 2017
    Applicants: ANGES MG, INC., OSAKA UNIVERSITY, DS PHARMA ANIMAL HEALTH CO., LTD.
    Inventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Hiroshi KORIYAMA, Hideki TOMIOKA, Kenji NAOHARA